SecBot SecBot
SECBOTREPLAY Home › Report › TLX

TLX · Telix Pharmaceuticals announced FDA approval of Pixclara®…

Telix Pharmaceuticals Limited · PRESS-RELEASE filed Sep 14, 2026 at 06:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Sep 14, 2026 at 06:30 ET

Telix Pharmaceuticals announced FDA approval of Pixclara® (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma (brain cancer), for differentiating recurrent or progressive glioma from treatment-related change in adults and pediatric patients. This approval addresses a significant unmet need in a market with ~24,000 new U.S. glioma cases annually and reinforces Telix's leadership in theranostics, expanding its commercial precision diagnostics portfolio alongside Illuccix and Gozellix. The approval is a transformative catalyst for Telix, particularly as an early-stage biotech with a first-in-class commercial asset in a new indication, likely driving substantial stock appreciation.

  • FDA approved Pixclara (floretyrosine F 18) for PET imaging to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients 1 month+
  • Pixclara is the first FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer)
  • Approximately 24,000 new glioma cases are diagnosed in the U.S. each year
  • FET-PET imaging is recommended in international clinical practice guidelines including NCCN Guidelines

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access